Experience

Sandoz Inc. v. AbbVie Biotechnology, Ltd

Sandoz, Inc.

AbbVie Biotechnology, Ltd

Successfully represented AbbVie in inter partes review (IPR) challenges related to Humira®.

Sandoz, Inc. v. AbbVie Biotechnology, Ltd, IPR2018-00002, -00156, IPR2017 -01824, -02106, -02105, PTAB, Judges Ankenbrand, Hulse, Mitchell

Related Professionals

William B. Raich, Ph.D.
Partner
Washington, DC
+1 202 408 4210
Email
Charles T. Collins-Chase
Partner
Washington, DC
+1 202 408 4108
Email

Related Practices

Appeals, Issues, and Legal Strategy

Federal Circuit and Supreme Court Appeals

Patent Office Invalidation Proceedings

PTAB Invalidation Proceedings: IPR and PGR

Related Industries

Life Sciences

Pharmaceutical

Related Experiences

Finnegan client AbbVie secures non-institution decisions for Humira® patents

AbbVie Biotechnology, Ltd

AbbVie Inc. v. Sandoz Inc.

AbbVie Inc.

AbbVie secures four non-institution decisions for Humira® patent

AbbVie Biotechnology, Ltd.

AbbVie Biotechnology; Abbott GmbH Ltd. v. InterLab Limited; Merck-Serono Limited

AbbVie Biotechnology; Abbott GmbH Ltd.

Abbott Biotechnology Ltd. v. Centocor Ortho Biotech Inc. 

Abbott Biotechnology Ltd.

Multiple settlement and license agreements for AbbVie, Inc.

AbbVie, Inc.

Coalition for Affordable Drugs IV LLC v.  Pharmacyclics, Inc.

AbbVie Inc.; Janssen Biotech, Inc.; Pharmacyclics LLC; Pharmacyclics, Inc.

Sandoz Inc. v. Boehringer Ingelheim International GmbH et al.

Boehringer Ingelheim International GmbH et al.

AbbVie Inc. v. Hospira, Inc. 

AbbVie Inc.

Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.